Innate Pharma (OTC:IPHYF)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Wednesday.

Shares of Innate Pharma (IPHYF) remained flat at $12.96 on Wednesday. Innate Pharma has a 12-month low of $10.72 and a 12-month high of $16.55. The firm has a market capitalization of $699.74 million and a P/E ratio of 48.18. The company’s 50-day moving average price is $12.54 and its 200 day moving average price is $12.40.

WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/innate-pharma-iphyf-rating-reiterated-by-hc-wainwright/1536366.html.

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.